RU2019113758A - Конъюгат "цистеин-модифицированное антитело-лекарственное средство" и способ его получения - Google Patents
Конъюгат "цистеин-модифицированное антитело-лекарственное средство" и способ его получения Download PDFInfo
- Publication number
- RU2019113758A RU2019113758A RU2019113758A RU2019113758A RU2019113758A RU 2019113758 A RU2019113758 A RU 2019113758A RU 2019113758 A RU2019113758 A RU 2019113758A RU 2019113758 A RU2019113758 A RU 2019113758A RU 2019113758 A RU2019113758 A RU 2019113758A
- Authority
- RU
- Russia
- Prior art keywords
- cysteine
- antibody
- cytotoxin
- light chain
- conjugate
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title claims 2
- 229940125644 antibody drug Drugs 0.000 title 1
- 239000002619 cytotoxin Substances 0.000 claims 15
- 235000018417 cysteine Nutrition 0.000 claims 11
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 11
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 7
- 101710112752 Cytotoxin Proteins 0.000 claims 5
- 231100000599 cytotoxic agent Toxicity 0.000 claims 5
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 3
- 150000001413 amino acids Chemical group 0.000 claims 3
- 238000003780 insertion Methods 0.000 claims 3
- 230000037431 insertion Effects 0.000 claims 3
- 125000006239 protecting group Chemical group 0.000 claims 3
- 238000005277 cation exchange chromatography Methods 0.000 claims 2
- 239000003638 chemical reducing agent Substances 0.000 claims 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 2
- 238000000108 ultra-filtration Methods 0.000 claims 2
- MFRNYXJJRJQHNW-DEMKXPNLSA-N (2s)-2-[[(2r,3r)-3-methoxy-3-[(2s)-1-[(3r,4s,5s)-3-methoxy-5-methyl-4-[methyl-[(2s)-3-methyl-2-[[(2s)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-DEMKXPNLSA-N 0.000 claims 1
- WMAXWOOEPJQXEB-UHFFFAOYSA-N 2-phenyl-5-(4-phenylphenyl)-1,3,4-oxadiazole Chemical compound C1=CC=CC=C1C1=NN=C(C=2C=CC(=CC=2)C=2C=CC=CC=2)O1 WMAXWOOEPJQXEB-UHFFFAOYSA-N 0.000 claims 1
- FJHBVJOVLFPMQE-QFIPXVFZSA-N 7-Ethyl-10-Hydroxy-Camptothecin Chemical compound C1=C(O)C=C2C(CC)=C(CN3C(C4=C([C@@](C(=O)OC4)(O)CC)C=C33)=O)C3=NC2=C1 FJHBVJOVLFPMQE-QFIPXVFZSA-N 0.000 claims 1
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 claims 1
- 230000001268 conjugating effect Effects 0.000 claims 1
- 230000021615 conjugation Effects 0.000 claims 1
- 230000003647 oxidation Effects 0.000 claims 1
- 238000007254 oxidation reaction Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Claims (14)
1. Конъюгат «цистеин-модифицированное антитело-цитотоксин», содержащий антитело и цитотоксин, где антитело содержит встроенный цистеин в участке встраивания цистеина, где участок встраивания цистеина включает положение 205 константной области легкой цепи каппа/λ по системе нумерации по Kabat, положение 206 константной области легкой цепи по системе нумерации по Kabat или положение 439 константной области тяжелой цепи IgG по системе нумерации по Kabat.
2. Конъюгат «цистеин-модифицированное антитело-цитотоксин» по п.1, где участок встраивания цистеина содержит аминокислотную последовательность, выбранную из LC-205ins: GLSSPCVTKSF, LC-206ins: GLSSPVCTKSF, и HC-439ins: TQKSLSCLSPGK, и где "C" является встроенным цистеином в положении 205 константной области легкой цепи, положении 206 константной области легкой цепи или положении 439 константной области тяжелой цепи.
3. Конъюгат «цистеин-модифицированное антитело-цитотоксин» по п.1, где встроенный цистеин содержит свободную тиоловую группу, где цитотоксин конъюгируют со свободной тиоловой группой посредством линкера, где антитело содержит легкую цепь, имеющую аминокислотную последовательность, выбранную из GLSSPCVTKSF и GLSSPVCTKSF, где антитело содержит тяжелую цепь, имеющую аминокислотную последовательность TQKSLSCLSPGK, и где C является встроенным цистеином в положении 205 легкой цепи, положении 206 легкой цепи или положении 439 тяжелой цепи антитела.
4. Конъюгат «цистеин-модифицированное антитело-цитотоксин» по п.1, где антитело содержит легкую цепь, где легкая цепь имеет изотип каппа (κ) или лямбда (λ).
5. Конъюгат «цистеин-модифицированное антитело-цитотоксин» по п.1, где антитело содержит тяжелую цепь, где тяжелая цепь имеет изотип IgG1, IgG2, IgG3 или IgG4.
6. Конъюгат «цистеин-модифицированное антитело-цитотоксин» по п.1, где встроенный цистеин содержит тиоловую группу (-SH).
7. Конъюгат «цистеин-модифицированное антитело-цитотоксин» по п.6, где тиоловая группа сконфигурирована для химической конъюгации.
8. Конъюгат «цистеин-модифицированное антитело-цитотоксин» по п. 1, где цитотоксин выбран из MMAE, MMAF, PBD, SN-38, Dox или их производного.
9. Способ получения конъюгата «цистеин-модифицированное антитело-цитотоксин» по п.1, включающий
восстановление антитела с помощью восстановителя для получения восстановленного антитела, где антитело содержит встроенный цистеин, содержащий тиоловую группу, экранированную защитной группой, и где восстановленное антитело содержит встроенный цистеин, из которого защитная группа удалена для получения свободной тиоловой группы,
удаление защитной группы и восстановителя посредством катионообменной хроматографии или ультрафильтрации,
окисление восстановленного антитела для получения окисленного антитела, содержащего межцепочечную дисульфидную связь,
конъюгацию линкера-цитотоксина со свободной тиоловой группой на встроенном цистеине для получения конъюгата «цистеин-модифицированное антитело-цитотоксин», и
удаление неконъюгированного линкера-цитотоксина посредством катионообменной хроматографии или ультрафильтрации.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610876568.9 | 2016-10-08 | ||
CN201610876568 | 2016-10-08 | ||
PCT/CN2017/104706 WO2018064964A1 (zh) | 2016-10-08 | 2017-09-30 | 半胱氨酸改造的抗体-毒素偶联物及其制备方法 |
Publications (3)
Publication Number | Publication Date |
---|---|
RU2019113758A true RU2019113758A (ru) | 2020-11-09 |
RU2019113758A3 RU2019113758A3 (ru) | 2020-12-25 |
RU2762594C2 RU2762594C2 (ru) | 2021-12-21 |
Family
ID=61533952
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2019113758A RU2762594C2 (ru) | 2016-10-08 | 2017-09-30 | Конъюгат "цистеин-модифицированное антитело-лекарственное средство" и способ его получения |
Country Status (11)
Country | Link |
---|---|
US (1) | US11484605B2 (ru) |
EP (1) | EP3524273A4 (ru) |
JP (1) | JP6998386B2 (ru) |
KR (2) | KR102579211B1 (ru) |
CN (2) | CN107789630A (ru) |
AU (1) | AU2017340314B2 (ru) |
CA (1) | CA3039559A1 (ru) |
IL (1) | IL265838B2 (ru) |
RU (1) | RU2762594C2 (ru) |
SG (1) | SG11201903084UA (ru) |
WO (1) | WO2018064964A1 (ru) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108743968B (zh) * | 2017-06-20 | 2022-04-19 | 成都百利多特生物药业有限责任公司 | 半胱氨酸改造的抗体-毒素偶联物(tdc)定点偶联位点筛选 |
CN110872339A (zh) * | 2018-08-30 | 2020-03-10 | 中国人民解放军军事科学院军事医学研究院 | 含有芳硝基的连接子、含连接子的抗体偶联药物及连接子的用途 |
WO2020233174A1 (zh) * | 2019-05-20 | 2020-11-26 | 烟台迈百瑞国际生物医药有限公司 | 一种抗体药物偶联物中间体的一锅法制备工艺 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1791565B1 (en) * | 2004-09-23 | 2016-04-20 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
CA2683568A1 (en) * | 2007-05-08 | 2008-11-20 | Genentech, Inc. | Cysteine engineered anti-muc16 antibodies and antibody drug conjugates |
TW200918089A (en) * | 2007-07-16 | 2009-05-01 | Genentech Inc | Humanized anti-CD79b antibodies and immunoconjugates and methods of use |
AU2008312457B2 (en) * | 2007-10-19 | 2014-04-17 | Genentech, Inc. | Cysteine engineered anti-TENB2 antibodies and antibody drug conjugates |
SI2657253T1 (sl) * | 2008-01-31 | 2017-10-30 | Genentech, Inc. | Protitelesa proti CD79b in imunokonjugati in postopki za uporabo |
EP2507381A4 (en) * | 2009-12-04 | 2016-07-20 | Hoffmann La Roche | PLURISPECIFIC ANTIBODIES, ANTIBODY ANALOGUES, COMPOSITIONS AND METHODS |
CN105143271A (zh) * | 2013-02-08 | 2015-12-09 | Irm责任有限公司 | 用于修饰抗体以制备免疫缀合物的特定位点 |
WO2015157595A1 (en) * | 2014-04-11 | 2015-10-15 | Medimmune, Llc | Conjugated compounds comprising cysteine-engineered antibodies |
WO2016131769A2 (en) * | 2015-02-16 | 2016-08-25 | Lonza Ltd | Antibodies |
CN106467575B (zh) * | 2015-08-18 | 2020-07-31 | 四川百利药业有限责任公司 | 半胱氨酸改造的抗体-毒素偶联物 |
US20170216452A1 (en) * | 2015-11-30 | 2017-08-03 | Pfizer Inc. | Antibodies and antibody fragments for site-specific conjugation |
CN106866822A (zh) * | 2016-12-25 | 2017-06-20 | 四川百利药业有限责任公司 | 半胱氨酸改造的抗体‑毒素偶联物 |
-
2017
- 2017-09-29 CN CN201710910870.6A patent/CN107789630A/zh active Pending
- 2017-09-29 CN CN202311413663.1A patent/CN117398475A/zh active Pending
- 2017-09-30 US US16/339,719 patent/US11484605B2/en active Active
- 2017-09-30 JP JP2019540482A patent/JP6998386B2/ja active Active
- 2017-09-30 CA CA3039559A patent/CA3039559A1/en active Pending
- 2017-09-30 RU RU2019113758A patent/RU2762594C2/ru active
- 2017-09-30 KR KR1020227044769A patent/KR102579211B1/ko active IP Right Grant
- 2017-09-30 EP EP17857845.6A patent/EP3524273A4/en active Pending
- 2017-09-30 KR KR1020197013122A patent/KR102480873B1/ko active IP Right Grant
- 2017-09-30 AU AU2017340314A patent/AU2017340314B2/en active Active
- 2017-09-30 IL IL265838A patent/IL265838B2/en unknown
- 2017-09-30 WO PCT/CN2017/104706 patent/WO2018064964A1/zh unknown
- 2017-09-30 SG SG11201903084UA patent/SG11201903084UA/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2017340314B2 (en) | 2021-04-29 |
CN107789630A (zh) | 2018-03-13 |
CN117398475A (zh) | 2024-01-16 |
KR102579211B1 (ko) | 2023-09-15 |
US11484605B2 (en) | 2022-11-01 |
KR102480873B1 (ko) | 2022-12-26 |
KR20230003663A (ko) | 2023-01-06 |
JP6998386B2 (ja) | 2022-02-10 |
IL265838A (en) | 2019-06-30 |
US20200129635A1 (en) | 2020-04-30 |
CA3039559A1 (en) | 2018-04-12 |
KR20190065374A (ko) | 2019-06-11 |
EP3524273A1 (en) | 2019-08-14 |
RU2019113758A3 (ru) | 2020-12-25 |
IL265838B2 (en) | 2024-03-01 |
JP2019533017A (ja) | 2019-11-14 |
AU2017340314A1 (en) | 2019-05-02 |
WO2018064964A1 (zh) | 2018-04-12 |
RU2762594C2 (ru) | 2021-12-21 |
SG11201903084UA (en) | 2019-05-30 |
IL265838B1 (en) | 2023-11-01 |
EP3524273A4 (en) | 2020-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2005218642B2 (en) | Partially loaded antibodies and methods of their conjugation | |
HRP20181069T1 (hr) | Antagonistička protutijela na il-17 | |
JP2019163319A5 (ru) | ||
HRP20191462T1 (hr) | Antitijela usmjerena protiv her-3 i njihove uporabe | |
CY1124289T1 (el) | Ανοσοσυζευμα που περιλαμβανει εξανθρωποποιημενα αντισωματα rs7 | |
RU2019113758A (ru) | Конъюгат "цистеин-модифицированное антитело-лекарственное средство" и способ его получения | |
JP2017518304A5 (ru) | ||
RS54163B1 (en) | ANTI-CD22 ANTIBODIES, THEIR IMMUNCONJUGATES AND THEIR USE | |
RU2016111137A (ru) | Сконструированные конъюгаты против dll3 и способы применения | |
TNSN06087A1 (en) | Therapeutic binding molecules | |
PE20020871A1 (es) | Moleculas de enlace terapeuticas | |
HRP20130922T1 (hr) | U potpunosti humana protutijela protiv humanog 4-1bb (cd137) | |
JP2016523810A5 (ru) | ||
BR0112086A (pt) | Anticorpos para mcp-1 humano | |
RU2010126078A (ru) | Антитело против nr10 и его применение | |
RU2015151505A (ru) | Антитела, направленные к белку запрограммированной гибели клетки-1 (pd-1) | |
DE60141043D1 (de) | Rekombinante anti-cd30-antikörper und deren verwendungen | |
AR035581A1 (es) | Anticuerpos para il-1beta humana | |
JP2015531750A5 (ru) | ||
CU23292B7 (es) | Anticuerpos monoclonales humanos de ctla-4 | |
RU2016129894A (ru) | Ковалентно связанные конъюгаты хеликар-антитело против хеликара и их применения | |
ZA200508389B (en) | Humanized antibodies to interferon alpha receptor-1(IFNAR-1) | |
CR8331A (es) | Reconocimiento dirigido de la vasculatura tumoral usando el anticuerpo l19 contra ed-8 de fibronectina marcado radioactivamente | |
JP2019533017A5 (ru) | ||
FI3773738T3 (fi) | Vasta-aine-lääkekonjugaatteja ja niiden käyttöjä syövän hoitamiseksi |